APA
Bahl A., Masson S., Malik Z., Birtle A. J., Sundar S., Jones R. J., James N. D., Mason M. D., Kumar S., Bottomley D., Lydon A., Chowdhury S., Wylie J. & de Bono J. S. (20160217). Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279). : BJU international.
Chicago
Bahl Amit, Masson Susan, Malik Zafar, Birtle Alison J, Sundar Santhanam, Jones Rob J, James Nicholas D, Mason Malcolm D, Kumar Satish, Bottomley David, Lydon Anna, Chowdhury Simon, Wylie James and de Bono Johann S. 20160217. Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279). : BJU international.
Harvard
Bahl A., Masson S., Malik Z., Birtle A. J., Sundar S., Jones R. J., James N. D., Mason M. D., Kumar S., Bottomley D., Lydon A., Chowdhury S., Wylie J. and de Bono J. S. (20160217). Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279). : BJU international.
MLA
Bahl Amit, Masson Susan, Malik Zafar, Birtle Alison J, Sundar Santhanam, Jones Rob J, James Nicholas D, Mason Malcolm D, Kumar Satish, Bottomley David, Lydon Anna, Chowdhury Simon, Wylie James and de Bono Johann S. Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279). : BJU international. 20160217.